Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Google Secures Pentagon AI Deal for Classified Projects 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
AMES, Iowa, May 08, 2017 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in the following upcoming investor conferences:
- Bank of America Merrill Lynch 2017 Health Care Conference on May 18 in Las Vegas, NV
- Jefferies 2017 Global Healthcare Conference on June 8 at 11:30am ET in New York City
A live webcast of the Jefferies conference presentation will be on the Company's website at www.newlinkgenetics.com in the "Investors & Media" section under "Events and Presentations."
About NewLink Genetics Corporation
NewLink Genetics is a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' product candidates are designed to harness multiple components of the immune system to combat cancer. For more information, please visit http://www.newlinkgenetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include any statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink Genetics makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics' Annual Report on Form 10-K for the year ended December 31, 2016 and other reports filed with the U.S. Securities and Exchange Commission (SEC). The forward-looking statements in this press release represent NewLink Genetics' views as of the date of this press release. NewLink Genetics anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics' views as of any date subsequent to the date of this press release.
Investor Relations Contact: Lisa Miller Director of Investor Relations NewLink Genetics (515) 598-2555 [email protected] Investor and Media Contacts: Beth Kurth, VP LaVoieHealthScience (617) 374-8800, ext. 106 [email protected] Sharon Correia, VP LaVoieHealthScience (617) 374-8800, ext. 105 [email protected]
